Clinical Trials Logo

Hypercholesterolemia clinical trials

View clinical trials related to Hypercholesterolemia.

Filter by:

NCT ID: NCT03952169 Recruiting - Clinical trials for Primary Hypercholesterolemia

Effect of Probiotics on Lipid Management

Start date: May 12, 2019
Phase: N/A
Study type: Interventional

Dysbiosis of gut microbiota has been reported to be involved in the development of hypercholesterolemia in both humans and animal models. Probiotics have been reported to have ameliorative effects in murine models. However, whether probiotics could help alleviate dyslipidemia in adults remain obscure.

NCT ID: NCT03949374 Completed - Clinical trials for Hypercholesterolemia

Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients

Start date: October 23, 2015
Phase: Phase 4
Study type: Interventional

This 8 weeks, prospective, single center, randomized, open-label, parallel-group, non-inferiority study was performed from October 2015 to April 2018. This study as designed to evaluate the efficacy and safety of 10mg of the generic formulation (rosuvastatin, ROVASRO®) compared to the reference formulation (rosuvastatin, CRESTOR®) in patients with primary hypercholesterolemia and complex dyslipidemia.

NCT ID: NCT03947866 Not yet recruiting - Clinical trials for Hypercholesterolemia

Ezetimibe-Simvastatin Evaluation Study

ZEUS
Start date: June 1, 2019
Phase:
Study type: Observational

The study purpose is to assess the efficacy of the fixed combination of ezetimibe-simvastatin in patients with hypercholesterolemia not responding to statin monotherapy in achieving the blood plasma LDL-C target as defined by the ESC / EAS Guideline, of 2016.

NCT ID: NCT03934320 Enrolling by invitation - Clinical trials for Familial Hypercholesterolemia

Improving Identification of Familial Hypercholesterolaemia in Primary Care (FAMCAT)

FAMCAT
Start date: June 12, 2017
Phase: N/A
Study type: Interventional

Multi-centre, non-randomised, non-controlled quasi-experimental study with nested qualitative study and economic appraisal. Improving the identification of patients at high risk of cardiovascular disease in primary care, caused by conditions such as familial hypercholesterolaemia (FH), is a well-recognised national priority to prevent morbidity and mortality by early effective intervention. This study will prospectively evaluate the clinical utility of the new primary care FH identification tool (FAMCAT) for identifying undiagnosed FH in routine primary care practice; and to assess its appropriateness, acceptability and cost-effectiveness. This study will answer the following research questions (RQ): 1. What is the detection rate for new genetically-confirmed FH cases using the FAMCAT algorithm? 2. Is the FAMCAT tool appropriate and acceptable to practitioners and patients? 3. How can the FAMCAT tool be optimised to improve identification of FH? 4. What is the potential cost-effectiveness of the FAMCAT tool compared with current practice to identify patients with FH? 5. Can the FAMCAT intervention be improved? 6. What definitive study design and outcome measures are needed to provide robust evidence on whether to introduce FAMCAT into primary care practice? RQ(1) & (3) will be answered by a quasi-experimental diagnostic accuracy study; RQ(2) & (5) answered by qualitative study; RQ (4) answered by economic appraisal and RQ(6) informed by all previous studies.

NCT ID: NCT03933293 Not yet recruiting - Clinical trials for Homozygous Familial Hypercholesterolemia

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

Start date: April 2019
Phase: Phase 2
Study type: Interventional

AK102 is being developed for the treatment of HoFH. The study will be conducted in 2 parts, part 1 is open label, single arm study to evaluate the safety, tolerability and efficacy of PCSK9 inhibitor AK102, and part 2 is double blind, randomized, placebo controlled study to evaluate the efficacy and safety of PCSK9 inhibitor AK102. The treatment period will last 12 week.

NCT ID: NCT03929198 Completed - Obesity Clinical Trials

Translation of Pritikin Program to the Community

Prit-TN
Start date: September 27, 2018
Phase: N/A
Study type: Interventional

The broad, long-term aims of this scope of work are to investigate the effects of the Pritikin Program to the general population. The study will test the effects on individuals from the community with dysfunctional lipids, blood pressure and glycemic control. To assess the effectiveness of the Pritikin Program in the community, the effects of Pritikin lifestyle intervention on overall health will be investigated.

NCT ID: NCT03916016 Completed - Obesity Clinical Trials

Sí Texas Hope Family Health Center

Start date: December 9, 2015
Phase: N/A
Study type: Interventional

This study evaluated whether uninsured patients living at or below 200% of the federal poverty level who received enhanced, culturally-relevant, integrated behavioral health services were more likely to improve health outcomes after 12 months compared to similar patients receiving usual care from Hope Family Health Center (HFHC), a charitable community clinic. The study employed a randomized control trial (RCT) design where intervention participants receiving integrated care at HFHC were compared to control participants receiving usual care at HFHC. Patients were placed in each group using simple random assignment. Demographic and health outcome data were collected from intervention and control participants at baseline. Health outcome data were subsequently collected at 6-month and 12-month follow-up points.

NCT ID: NCT03900169 Not yet recruiting - Clinical trials for Familial Hypercholesterolemia

Familial Hypercolerstremia as Risk Factor in Stemi Patient Who Underwent Ppci

Start date: June 1, 2019
Phase:
Study type: Observational

Famulial hypercolerstremia as risk factor

NCT ID: NCT03885921 Completed - Clinical trials for Hypercholesterolemia

Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)

Start date: October 25, 2000
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the long-term safety and tolerability of ezetimibe (SCH 058235/MK-0653) 10 mg dosed daily and co-administered with either atorvastatin or simvastatin for up to 24 months in participants with homozygous familial hypercholesterolemia (FH). Following completion of the 12-week, double-blind, efficacy and safety parent study (P01030/MK-0653-018; NCT03884452) participants will be offered entry into this open-label, 24-month extension study.

NCT ID: NCT03884452 Completed - Clinical trials for Familial Hypercholesterolemia

Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)

Start date: May 3, 2000
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy and the safety of ezetimibe (SCH 58235) co-administered with either atorvastatin or simvastatin in participants with homozygous familial hypercholesterolemia (FH).